Tamsulosin Hydrochloride Capsule
Product Images NDC 60760-598

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 60760-598). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary�s Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tamsulosin 60760 598 90

Label for Tamsulosin Hydrochloride capsules, USP 0.4 mg, in a package of 90 capsules. The label indicates it is manufactured by Aurobindo Pharma USA, Inc., and packaged by St. Mary's Medical Park Pharmacy in Oro Valley, AZ. It includes storage instructions to keep at controlled room temperature 15°-30°C (59°-86°F) and notes Rx only.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

A line graph showing mean plasma concentrations of Tamsulosin Hydrochloride over time following a single 0.4 mg dose of oral capsules. The x-axis represents time in hours up to 36 hours, and the y-axis shows plasma concentration in ng/mL. Two lines compare concentrations under fasted and fed conditions in eight subjects.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

A line graph titled 'Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1' showing mean change on the Y-axis and duration of treatment (weeks) on the X-axis. It compares three treatment groups: 0.8 mg, 0.4 mg, and placebo. The graph tracks symptom score decreases over 13 weeks plus the last observation carried forward (LOCF) with sample sizes noted at each time point.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

A line graph titled 'Figure 2B Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2.' It shows mean change values on the vertical axis and duration of treatment in weeks on the horizontal axis, comparing three groups: 0.8 mg, 0.4 mg, and placebo. Each group is represented by different markers: circles for 0.8 mg, triangles for 0.4 mg, and squares for placebo. The graph shows the symptom score changes over treatment periods up to 13 weeks plus LOCF data.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

A line graph titled 'Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1,' showing mean change in mL/sec over a treatment duration of up to 13 weeks. It compares three groups: 0.8 mg dose, 0.4 mg dose of tamsulosin hydrochloride, and placebo. The graph indicates differences in peak urine flow rate changes across these groups over time.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

A line graph titled 'Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2' showing changes in mean peak urine flow rate over 13 weeks of treatment. The x-axis represents duration of treatment in weeks, and the y-axis represents mean change in mL/sec. The graph compares three treatments: 0.8 mg, 0.4 mg, and placebo, with mean urine flow rate changes increasing more for 0.4 mg and 0.8 mg treatments compared to placebo over time.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure of Tamsulosin Hydrochloride showing its molecular components and arrangement. The diagram includes functional groups and the hydrochloride (HCl) component as part of the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.